|
|
Vol. 15.15 – 13 August, 2026
|
|
|
|
|
|
|
|
|
Researchers identified circulating tumor DNA clearance and molecular residual disease as key biomarkers of nivolumab benefit and recurrence risk in resectable non-small cell lung cancer. [Nature]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
Scientists identified B cell lymphoma 9 (BCL9) as a key upstream regulator implicated in idiopathic pulmonary fibrosis pathogenesis. They demonstrated that BCL9 drives the macrophage M2 program through the MerTK-ERK-SPP1 axis.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
The authors demonstrated that intratracheal administration of self-amplifying mRNA-lipid nanoparticles can cause significant side effects that can be linked to innate immune cell recruitment and cytokine release in the lungs.
[ACS Nano]
|
|
|
|
|
|
Investigators explored the p.C97W variant in WAP four-disulfide core domain protein 2 (WFDC2), proposed as a new genetic origin of respiratory distress.
[Nature Communications]
|
|
|
|
|
|
Scientists found that Mpr1/Pad1 N-terminal domain-containing protein (MPND) is frequently deleted, and its expression is significantly downregulated in NSCLC tumor tissues.
[Cancer Research]
|
|
|
|
|
|
Researchers identified MIC19, a key subunit of mitochondrial contact site and cristae organizing system complex, as an essential regulator of hypoxia-induced mitophagy in NSCLC.
[Oncogene]
|
|
|
|
|
|
Investigators showed that DLL3-targeting variable domain of heavy-chain–only antibodies (VHH)-based chimeric antigen receptor T (CAR-T) cells exhibit potent antitumor activity against small cell lung cancer, supporting their potential as a new immunotherapy for DLL3-positive tumors. [Molecular Cancer Therapeutics]
|
|
|
|
|
|
|
|
Scientists summarize the current knowledge of the fucosyltransferase family and critically evaluate the evidence linking aberrant fucosylation to asthma pathogenesis. [Clinical Reviews in Allergy & Immunology]
|
|
|
|
|
|
|
|
UCLA researchers received a $1.2 million grant to investigate whether a common diabetes drug could slow early-stage lung adenocarcinoma and help prevent future lung cancers.
[UCLA Health]
|
|
|
|
|
|
Dr. James Willey, a pulmonary physician at University of Toledo (UToledo) Health and holder of the George Isaac Chair In Cancer Research, has received a $200,000 Stand Up To Cancer grant to support a simple, noninvasive screening test for lung cancer. [University of Toledo]
|
|
|
|
|
|
|
|
October 23-27, 2026 Madrid, Spain
|
|
|
|
|
|
|
|
|
|
|
Thomas Jefferson University – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
Cedars Sinai Medical Center – Los Angeles, California, United States
|
|
|
|
|
|
|
Boston University – Boston, Massachusetts, United States
|
|
|
|
|
|
|
UmeÃ¥ University – UmeÃ¥, Sweden
|
|
|
|
|
|